Citius Oncology, Inc.
CTOR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001851484
No open-market purchases or sales by Citius Oncology, Inc. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $9.20M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Citius Oncology, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Citius Oncology, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Holubiak Myron Z | Secretary | 850,000 | Dec 22, 2025 | 1 |
| McGrath Dennis M | Director | 300,000 | Dec 22, 2025 | 1 |
| Mazur Leonard L | Chief Executive Officer | 1,700,000 | Dec 22, 2025 | 1 |
| Dutia Suren G | Director | 300,000 | Dec 22, 2025 | 1 |
| Mayersohn Joel David | Director | 321,228 | Dec 22, 2025 | 1 |
| Webb Carol | Director | 300,000 | Dec 22, 2025 | 1 |
| Holuka Eugene Myron | Director | 300,000 | Dec 22, 2025 | 1 |
| Bartushak Jaime | Chief Financial Officer | 825,000 | Dec 22, 2025 | 1 |
| Czuczman Myron | Chief Medical Officer | 825,000 | Dec 22, 2025 | 1 |
| Smith Robert Joseph | Director | 300,000 | Dec 22, 2025 | 1 |
| Citius Pharmaceuticals, Inc. | 10% Owner | – | Aug 14, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
No insider trades match these filters.